Spectral AI Taps Veteran CFO to Steer AI Device to Market

DALLAS, TX – April 08, 2026 – Spectral AI, an artificial intelligence firm on the cusp of revolutionizing medical diagnostics, has appointed veteran finance executive David McGuire as its new Chief Financial Officer. The move, effective May 4, 2026, is a clear signal of the company's strategic shift from research and development to full-scale commercialization of its groundbreaking DeepView® System.

“David’s appointment as CFO is another important step in strengthening Spectral AI’s financial leadership and strategic readiness as we prepare for commercialization of the DeepView® System,” said Vincent S. Capone, Spectral AI’s Chief Executive Officer. “David is a seasoned public company executive with experience in global markets, finance, financial planning and analysis and internal controls, and we are excited to welcome him to our team. His appointment underscores our commitment to strong financial governance.”

A Strategic Hire for a Pivotal Transition

The appointment comes at what McGuire himself calls a “pivotal time” for the Dallas-based company. Spectral AI is awaiting a decision from the U.S. Food and Drug Administration (FDA) on its De Novo 510(k) marketing application for the DeepView System, a device poised to change how burn wounds are assessed. With a potential market launch on the horizon, the need for robust financial stewardship has never been greater.

McGuire brings over two decades of experience perfectly suited for this transition. His career is marked by leadership roles in publicly traded companies, where he was instrumental in scaling financial operations and navigating complex regulatory environments. Prior to joining Spectral AI, he served as Chief Accounting Officer at Solo Brands, Inc., a consumer products company, where he managed accounting, financial reporting, and internal controls. His background also includes a key tenure as Deputy Chief Financial Officer and Chief Accounting Officer at EZCORP, Inc., a multinational financial services provider, where he gained significant experience in capital markets activities.

This expertise in Sarbanes-Oxley (SOX) compliance, investor relations, and building scalable financial infrastructure for public companies is precisely what a growth-stage med-tech firm like Spectral AI requires as it moves to monetize years of intensive research and development.

The AI Revolution in Wound Care

At the heart of Spectral AI's mission is the DeepView System, a non-invasive device that combines multispectral imaging with proprietary AI algorithms. The technology aims to solve a long-standing problem in emergency medicine: accurately and quickly determining if a burn wound will heal on its own or if it will require surgery.

Traditionally, this assessment is made by experienced clinicians, a process that can be subjective and often requires a waiting period of several days to weeks to observe the wound's progression. DeepView, however, provides an objective, data-driven prediction in seconds. By analyzing how different wavelengths of light interact with tissue, the system's AI can “See the Unknown®” and distinguish between tissue that will heal and tissue that will not.

Clinical data has demonstrated the system's remarkable potential. In a landmark U.S. burn validation study, one of the largest of its kind, the DeepView System achieved 86.6% sensitivity in identifying non-healing tissue, significantly outperforming the 40.8% sensitivity rate of physicians' initial clinical assessments. Other studies have highlighted an overall accuracy of over 92% in predicting burn healing outcomes. This level of accuracy promises to reduce patient suffering, improve outcomes by enabling earlier intervention, and lower healthcare costs by avoiding unnecessary treatments or delayed surgeries.

While the company awaits its U.S. clearance, the DeepView System has already achieved UK Conformity Assessed (UKCA) marking, allowing for its use in the United Kingdom. The company is also exploring its application for other conditions, such as diabetic foot ulcers, where early and accurate assessment is critical.

Navigating the Complex Path to Market

Bringing a novel medical device to market is a formidable challenge, and McGuire will be at the financial helm as Spectral AI navigates these final hurdles. The company's financial health is that of a firm in transition. It has been heavily supported by contracts from the Biomedical Advanced Research and Development Authority (BARDA), which have funded clinical validation and the FDA submission process. Recent BARDA awards have bolstered its cash position, which stood at $15.4 million at the end of 2025.

However, as these R&D-focused contracts wind down, the company must prepare for a new revenue model based on product sales and service agreements. This involves not only scaling manufacturing and sales operations but also successfully navigating the complex world of medical device reimbursement to ensure physicians and hospitals are paid for using the technology.

McGuire's experience in financial planning and analysis will be critical in managing cash flow, allocating capital for the commercial launch, and communicating the company's long-term value proposition to investors. His track record of advising growing companies on finance and accounting transformation will be invaluable as Spectral AI builds the financial architecture necessary to support its growth ambitions.

A Proven Leader for a New Frontier

McGuire's career began with a 14-year tenure at Ernst & Young LLP, where he advised clients on complex accounting and financial reporting matters. His move from established consumer and financial services industries to the cutting edge of AI-driven medical technology highlights the universal importance of strong financial discipline in innovation.

In his new role, McGuire will be tasked with translating Spectral AI's profound technological and clinical achievements into sustainable financial success and long-term shareholder value. His appointment is a deliberate move to install a leader with the public company rigor and strategic financial acumen needed to guide Spectral AI through its most critical phase of growth.

“I am honored and excited to assume the role of CFO at this pivotal time in the Company’s history,” McGuire stated upon his appointment. “I look forward to collaborating with a talented team to advance our strategic priorities and enhance long-term shareholder value.” With its technology validated and its leadership team strengthened, Spectral AI appears fully equipped to make its mark on the future of wound care.